Prior SARS-CoV-2 infection enhances effectiveness of Pfizer-BioNTech vaccine

By | July 29, 2021
A study conducted by researchers in Qatar has found that Pfizer-BioNTech’s coronavirus disease 2019 (COVID-19) vaccine was more protective against infection with severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) among individuals who had previously been infected with the virus than among those who had not.